Trending...
- Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
- The New Monaco of the South (of Italy)
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
Download
Adam Lynch, Vice President, Corporate Development and External Affairs, NorthStar Medical Radioisotopes (Photo: Business Wire)
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Adam D. Lynch as Vice President, Corporate Development and External Affairs. In this new position, he brings to the Company more than 20 years of experience in the healthcare industry, most recently as interim Chief Financial Officer for a 200-bed acute care hospital. Mr. Lynch will report to NorthStar President and Chief Executive Officer Stephen Merrick.
More on Wisconsin Eagle
"Adam's strong leadership and proven experience in driving successful corporate development outcomes position him as a key contributor to NorthStar's continued growth as we expand awareness and availability of our domestically produced and environmentally sound medical radioisotope products with U.S. health systems," said Stephen Merrick, President and Chief Executive Officer of NorthStar. "As a key member of our leadership team, Adam will initially focus on working with health systems and other key stakeholders to help them realize the benefits of using technetium-99m (Tc-99m) derived from domestically produced, non-uranium based molybdenum-99 (Mo-99). Tc-99m is the most widely used medical imaging radioisotope, used in 40,000 patient procedures daily. Access to reliable, sustainable and diversified Tc-99m supply is of paramount importance for U.S. healthcare, the economy and the environment. Adam's strategic acumen and in-depth experience in healthcare, business and finance will help advance NorthStar in our next stage of corporate growth across the radiopharmaceutical industry, and we welcome him to the team."
"NorthStar has established itself as a leader in the rapidly expanding radiopharmaceutical sector by developing and delivering innovative solutions for reliable medical radioisotope supply," said Mr. Lynch. "I'm excited at the opportunity to be part of this impressive team at a pivotal moment in its growth, and look forward to contributing my strategic corporate development and finance experience to expand access to medical radioisotopes produced in the United States that are critical for healthcare. Together, we can ensure that we meet the needs of health systems across the country and the many millions of patients who can benefit from NorthStar's products."
Prior to joining NorthStar, Mr. Lynch served as an executive for Humboldt Park Health, which he led through the initial surge and secondary uptick in COVID-19 positive inpatients. Simultaneously, Mr. Lynch completed a $32.3 million financing and directed advocacy for what became $36.3 million in COVID-19 relief aid. Previously, he managed the divestiture of five business units for Northwestern Medicine and, as Group VP, oversaw post-merger integration for the Illinois Health and Hospital Association. Mr. Lynch has been an innovator in the healthcare industry. He launched the MetroChicago Health Information Exchange and was instrumental in the development of a health insurance company. Earlier roles included serving as Vice President at Principle Valuation, a specialty healthcare valuation and advisory firm and Citadel Group Limited, where he developed and invested more than $1.5 billion in medical real estate. Mr. Lynch has been recognized by the American College of Healthcare Executives (ACHE) with a Regent Award and is a Crain's Chicago 40 under 40 honoree. He is a former Regional Executive of Healthcare Financial Management Association (HFMA) and Past President of the First Illinois Chapter. Mr. Lynch is a graduate of the University of Wisconsin, Milwaukee.
More on Wisconsin Eagle
About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals. The Company's proprietary state-of-the art technology and proven management team have propelled it to the forefront of U.S. medical radioisotope production as the sole domestic producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m (Tc-99m), the standard of care in diagnostic imaging to assess the extent and severity of heart disease and cancer. NorthStar's unique Mo-99 production process is non-uranium based and environmentally friendly. NorthStar is expanding its industry-leading position in the emerging area of therapeutic radioisotopes, which are used in targeted radiopharmaceutical therapy to treat cancer, respiratory and other diseases. Using first-in-kind and environmentally-sound electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67). For more information about NorthStar's comprehensive radiopharmaceutical portfolio, visit: www.northstarnm.com.
Contacts
For NorthStar Medical Radioisotopes, LLC
Corporate:
Lisa Holst
Vice President Sales and Marketing
678-471-9027
lholst@northstarnm.com
Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
pestrem@northstarnm.com
Media:
Priscilla Harlan
781-799-7917
pharlan@shiningrockllc.com
Release Summary
NorthStar Medical Radioisotopes has expanded with the appointment of Adam Lynch as Vice President, Corporate Development and External Affairs.
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
For NorthStar Medical Radioisotopes, LLC
Corporate:
Lisa Holst
Vice President Sales and Marketing
678-471-9027
lholst@northstarnm.com
Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
pestrem@northstarnm.com
Media:
Priscilla Harlan
781-799-7917
pharlan@shiningrockllc.com
Adam Lynch, Vice President, Corporate Development and External Affairs, NorthStar Medical Radioisotopes (Photo: Business Wire)
- Adam Lynch, Vice President, Corporate Development and External Affairs, NorthStar Medical Radioisotopes (Photo: Business Wire)
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Adam D. Lynch as Vice President, Corporate Development and External Affairs. In this new position, he brings to the Company more than 20 years of experience in the healthcare industry, most recently as interim Chief Financial Officer for a 200-bed acute care hospital. Mr. Lynch will report to NorthStar President and Chief Executive Officer Stephen Merrick.
More on Wisconsin Eagle
- Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
- At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
- Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
- TAP Announces Open Auditions for 2026 Season
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
"Adam's strong leadership and proven experience in driving successful corporate development outcomes position him as a key contributor to NorthStar's continued growth as we expand awareness and availability of our domestically produced and environmentally sound medical radioisotope products with U.S. health systems," said Stephen Merrick, President and Chief Executive Officer of NorthStar. "As a key member of our leadership team, Adam will initially focus on working with health systems and other key stakeholders to help them realize the benefits of using technetium-99m (Tc-99m) derived from domestically produced, non-uranium based molybdenum-99 (Mo-99). Tc-99m is the most widely used medical imaging radioisotope, used in 40,000 patient procedures daily. Access to reliable, sustainable and diversified Tc-99m supply is of paramount importance for U.S. healthcare, the economy and the environment. Adam's strategic acumen and in-depth experience in healthcare, business and finance will help advance NorthStar in our next stage of corporate growth across the radiopharmaceutical industry, and we welcome him to the team."
"NorthStar has established itself as a leader in the rapidly expanding radiopharmaceutical sector by developing and delivering innovative solutions for reliable medical radioisotope supply," said Mr. Lynch. "I'm excited at the opportunity to be part of this impressive team at a pivotal moment in its growth, and look forward to contributing my strategic corporate development and finance experience to expand access to medical radioisotopes produced in the United States that are critical for healthcare. Together, we can ensure that we meet the needs of health systems across the country and the many millions of patients who can benefit from NorthStar's products."
Prior to joining NorthStar, Mr. Lynch served as an executive for Humboldt Park Health, which he led through the initial surge and secondary uptick in COVID-19 positive inpatients. Simultaneously, Mr. Lynch completed a $32.3 million financing and directed advocacy for what became $36.3 million in COVID-19 relief aid. Previously, he managed the divestiture of five business units for Northwestern Medicine and, as Group VP, oversaw post-merger integration for the Illinois Health and Hospital Association. Mr. Lynch has been an innovator in the healthcare industry. He launched the MetroChicago Health Information Exchange and was instrumental in the development of a health insurance company. Earlier roles included serving as Vice President at Principle Valuation, a specialty healthcare valuation and advisory firm and Citadel Group Limited, where he developed and invested more than $1.5 billion in medical real estate. Mr. Lynch has been recognized by the American College of Healthcare Executives (ACHE) with a Regent Award and is a Crain's Chicago 40 under 40 honoree. He is a former Regional Executive of Healthcare Financial Management Association (HFMA) and Past President of the First Illinois Chapter. Mr. Lynch is a graduate of the University of Wisconsin, Milwaukee.
More on Wisconsin Eagle
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
- Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals. The Company's proprietary state-of-the art technology and proven management team have propelled it to the forefront of U.S. medical radioisotope production as the sole domestic producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m (Tc-99m), the standard of care in diagnostic imaging to assess the extent and severity of heart disease and cancer. NorthStar's unique Mo-99 production process is non-uranium based and environmentally friendly. NorthStar is expanding its industry-leading position in the emerging area of therapeutic radioisotopes, which are used in targeted radiopharmaceutical therapy to treat cancer, respiratory and other diseases. Using first-in-kind and environmentally-sound electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67). For more information about NorthStar's comprehensive radiopharmaceutical portfolio, visit: www.northstarnm.com.
Contacts
For NorthStar Medical Radioisotopes, LLC
Corporate:
Lisa Holst
Vice President Sales and Marketing
678-471-9027
lholst@northstarnm.com
Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
pestrem@northstarnm.com
Media:
Priscilla Harlan
781-799-7917
pharlan@shiningrockllc.com
Release Summary
NorthStar Medical Radioisotopes has expanded with the appointment of Adam Lynch as Vice President, Corporate Development and External Affairs.
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
For NorthStar Medical Radioisotopes, LLC
Corporate:
Lisa Holst
Vice President Sales and Marketing
678-471-9027
lholst@northstarnm.com
Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
pestrem@northstarnm.com
Media:
Priscilla Harlan
781-799-7917
pharlan@shiningrockllc.com
0 Comments
Latest on Wisconsin Eagle
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
- The New Monaco of the South (of Italy)
- Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
- Lacy Hendricks Earns Prestigious MPM® Designation from NARPM®
- Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL)
- AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
- IQSTEL Enters 2026 from a Position of Strength Following Transformational Year Marked by N A S D A Q Uplisting, Record Revenue and First-Ever
- Are You Hiring The Right Heater Repair Company in Philly?
- Appliance EMT Expands Professional Appliance Repair Services to Hartford, Connecticut
- Java Holdings LLC Acquires +Peptide, Expanding Portfolio Across Coffee, Science, and Functional Nutrition
- OneSolution® Expands to Orlando with New Altamonte Springs Implant Center
- Indian Peaks Veterinary Hospital Launches Updated Dental Services Page for Boulder Pet Owners
- Dugan Air Donates $10,000 to Indian Creek Schools
- Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
- 2025: A Turning Point for Human Rights. CCHR Demands End to Coercive Psychiatry
- The 22% Tax Reality: Finland's New Gambling Law Creates a "Fiscal Trap" for Grey Market Casino Players
- Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion